[Recombinant probiotics: problems and prospects of their use for medicine and veterinary practice].
Approaches to designing a new probiotic class based on recombinant strains of bacteria that produce the predetermined therapeutic proteins are dealt with. The prospects of the approach are shown via studies of the biological properties of Bacillus subtilis 2335 strain transformed by the plasmid encoding the synthesis of human interferon alpha-2. The recombinant strain was demonstrated to preserve the high antagonistic activity of the parent culture (the bases of the probiotic biosporine) and to acquire marked antiviral properties due to interferon synthesis. The antiviral activity of the designed strain was shown by in vitro and in vivo experiments on experimental viral infections. By using this strain, the authors designed the new probiotic subaline, a promising biological agent for medicine and veterinary practice. Subalin has a number of advantages: it combines antibacterial and antiviral properties, is easy to use and prepare.